Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114920 · ClinicalTrials.gov registry record · Phase 2
Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
A Phase 2 study, sponsored by Graceway Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT00114920: Completed Phase 2 study, sponsored by Graceway Pharmaceuticals.
NCT00114920 is a Phase 2 study that has completed, run by Graceway Pharmaceuticals. The registered enrollment target is 88 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00114920, a Phase 2 study, has completed, sponsored by Graceway Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks. A second purpose is to evaluate the safety of the drug.
Interventions
- DRUG Resiquimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2004-03 |
| Phase | Phase 2 |
What the finished NCT00114920 record still lists
NCT00114920 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 1 intervention - of which Resiquimod is the first listed.
NCT00114920 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00114920 about?
NCT00114920 is a clinical study titled "Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults". The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks. A second purpose is to evaluate the safety of the drug.
What is the current status of trial NCT00114920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2004-03.
What interventions are being tested in trial NCT00114920?
The interventions under investigation include: Resiquimod (DRUG).
Who is sponsoring clinical trial NCT00114920?
This trial is sponsored by Graceway Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00114920's enrollment target sits among peer trials
88 803rd of 2000 higher than 1,191 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia